Posted by Michael Wonder on 29 Mar 2018
Decision to list eplerenone for the treatment of heart failure
29 March 2018 - PHARMAC is pleased to announce a decision to fund eplerenone (Inspra), subject to certain clinical criteria being met, in conjunction with the awarding of eplerenone bids as part of PHARMAC’s 2017/18 annual Invitation to Tender.
The 25 mg tablet form will be listed from 1 July 2018, and the 50 mg tablet form will be listed from 1 October 2018.
Sole Subsidised Supply Status and Hospital Supply Status will apply to both strengths of Pfizer’s Inspra brand of eplerenone tablets until 30 June 2021.
